MAXHEALTHNSEMax Healthcare Institute LimitedHighNeutral
Announced Wed, 13 Aug · 12:32 IST

Max Healthcare Institute Limited has informed the Exchange about Capacity addition

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF

MAXHEALTH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Max Healthcare reported strong Q1 FY26 (quarter ended June 30, 2025) consolidated results with revenue from operations at ₹2,02,757 lakhs, up about 31% year-on-year from ₹1,54,295 lakhs in Q1 FY25. Consolidated profit after tax rose roughly 30% YoY to ₹30,797 lakhs (vs ₹23,627 lakhs), with basic EPS at ₹3.17 (vs ₹2.43). Standalone revenue grew about 12% YoY to ₹69,402 lakhs and PAT grew about 8% to ₹16,603 lakhs. The Board also approved an Agreement to Lease with Goyal Agrim Infra Realty LLP to set up a ~130 bedded built-to-suit hospital in Dehradun, expected to be commissioned by 2028, with investment of ₹170–200 crore funded mainly through internal accruals. Network capacity currently stands at ~5,200 beds operating at over 76% utilization, and the new Dehradun hospital will focus on advanced oncology services.

Likely market impact

Strong double-digit revenue and profit growth signals robust operational momentum and likely positive sentiment, while the Dehradun expansion adds future bed capacity in a high-utilization market and supports long-term growth. Shareholders benefit from continued earnings expansion and a clear capex roadmap, though the new hospital will only contribute from 2028 onwards.